fluorouracil has been researched along with Facial Dermatoses in 39 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Facial Dermatoses: Skin diseases involving the FACE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Five per cent 5-fluorouracil (5-FU) cream is a well-established treatment for actinic keratosis (AK), and ingenol mebutate gel (IMB) is a novel topical field-directed therapy." | 9.20 | Evaluation of the tolerability and safety of a 0.015% ingenol mebutate gel compared to 5% 5-fluorouracil cream for the treatment of facial actinic keratosis: a prospective randomized trial. ( Samorano, LP; Sanches, JA; Torezan, LA, 2015) |
| "No long-term randomized controlled clinical trial has compared the efficacy of cryosurgery alone vs cryosurgery following fluorouracil applications for the treatment of actinic keratosis." | 9.11 | Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial. ( Furst, K; Jorizzo, J; Levy, SF; VandePol, C; Weiss, J, 2004) |
| "A cumulative meta-analysis was performed to determine the efficacy of imiquimod 5% cream, which presents a new alternative topical therapy for actinic keratosis, and to compare it to 5-fluorouracil for the treatment of actinic keratosis lesions of the face and scalp." | 8.82 | Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies. ( Davey, V; Gupta, AK; Mcphail, H, 2005) |
| "At 6-month posttreatment follow-up, recurrence of cleared lesions (no clinically visible lesions in treatment area) occurred in 39." | 6.80 | A prospective randomized exploratory study comparing the efficacy of once-daily topical 0.5% 5-fluorouracil in combination with 10.0% salicylic acid (5-FU/SA) vs. cryosurgery for the treatment of hyperkeratotic actinic keratosis. ( Dirschka, T; Dominicus, R; Karl, L; Rodríguez, R; Simon, JC; Willers, C, 2015) |
| "Keratoacanthoma is a benign tumor; however, it may cause massive destruction of normal tissue during its rapid growth phase." | 5.27 | Large keratoacanthomas in difficult locations treated with intralesional 5-fluorouracil. ( Hanke, CW; Parker, CM, 1986) |
| "Five per cent 5-fluorouracil (5-FU) cream is a well-established treatment for actinic keratosis (AK), and ingenol mebutate gel (IMB) is a novel topical field-directed therapy." | 5.20 | Evaluation of the tolerability and safety of a 0.015% ingenol mebutate gel compared to 5% 5-fluorouracil cream for the treatment of facial actinic keratosis: a prospective randomized trial. ( Samorano, LP; Sanches, JA; Torezan, LA, 2015) |
| "It is timely to compare the efficacy and tolerability of 2 actinic keratosis (AK) therapies--5% 5-fluorouracil (5-FU) cream and imiquimod cream." | 5.12 | Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp. ( Tanghetti, E; Werschler, P, 2007) |
| "No long-term randomized controlled clinical trial has compared the efficacy of cryosurgery alone vs cryosurgery following fluorouracil applications for the treatment of actinic keratosis." | 5.11 | Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial. ( Furst, K; Jorizzo, J; Levy, SF; VandePol, C; Weiss, J, 2004) |
| "A cumulative meta-analysis was performed to determine the efficacy of imiquimod 5% cream, which presents a new alternative topical therapy for actinic keratosis, and to compare it to 5-fluorouracil for the treatment of actinic keratosis lesions of the face and scalp." | 4.82 | Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies. ( Davey, V; Gupta, AK; Mcphail, H, 2005) |
| "At 6-month posttreatment follow-up, recurrence of cleared lesions (no clinically visible lesions in treatment area) occurred in 39." | 2.80 | A prospective randomized exploratory study comparing the efficacy of once-daily topical 0.5% 5-fluorouracil in combination with 10.0% salicylic acid (5-FU/SA) vs. cryosurgery for the treatment of hyperkeratotic actinic keratosis. ( Dirschka, T; Dominicus, R; Karl, L; Rodríguez, R; Simon, JC; Willers, C, 2015) |
| " Visible AK were counted, random skin biopsies performed, adverse effects monitored, and patients questioned about preference and perception of efficacy." | 2.68 | A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. ( Cockerell, CJ; Cox, SE; Cruz, PD; Freeman, RG; Lawrence, N, 1995) |
| "5-fluorouracil (5-FU) treatment is also widely utilized." | 1.31 | Cryopeeling (extensive cryosurgery) for treatment of actinic keratoses: an update and comparison. ( Chiarello, SE, 2000) |
| "Acanthosis nigricans is an uncommon skin condition characterized by hyperkeratosis and skin hyperpigmentation." | 1.30 | Malignant acanthosis nigricans: potential role of chemotherapy. ( Anderson, SH; Hudson-Peacock, M; Muller, AF, 1999) |
| "The rosacea was associated with episodes of diarrhoea." | 1.29 | [Carcinoid tumor with revealed by skin manifestation]. ( Cuny, JF; Grandidier, M; Reichert, S; Truchetet, F, 1994) |
| "Ten patients completed a weekly pulse dosing regimen for topical 5-fluorouracil therapy for multiple facial actinic keratoses." | 1.28 | Weekly pulse dosing: effective and comfortable topical 5-fluorouracil treatment of multiple facial actinic keratoses. ( Pearlman, DL, 1991) |
| "Keratoacanthoma is a benign tumor; however, it may cause massive destruction of normal tissue during its rapid growth phase." | 1.27 | Large keratoacanthomas in difficult locations treated with intralesional 5-fluorouracil. ( Hanke, CW; Parker, CM, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (25.64) | 18.7374 |
| 1990's | 7 (17.95) | 18.2507 |
| 2000's | 12 (30.77) | 29.6817 |
| 2010's | 9 (23.08) | 24.3611 |
| 2020's | 1 (2.56) | 2.80 |
| Authors | Studies |
|---|---|
| Alessi, DM | 1 |
| Azhdam, AM | 1 |
| Borrelli, M | 1 |
| Walker, JL | 1 |
| Siegel, JA | 1 |
| Sachar, M | 1 |
| Pomerantz, H | 1 |
| Chen, SC | 1 |
| Swetter, SM | 1 |
| Dellavalle, RP | 1 |
| Stricklin, GP | 1 |
| Qureshi, AA | 1 |
| DiGiovanna, JJ | 1 |
| Weinstock, MA | 1 |
| Petersen Vitello Kalil, CL | 1 |
| Herman Reinehr, CP | 1 |
| de Mattos Milman, L | 1 |
| Bakos, RM | 1 |
| Bhattacharjee, R | 1 |
| Kumaran, MS | 1 |
| Vinay, K | 1 |
| Simon, JC | 1 |
| Dominicus, R | 1 |
| Karl, L | 1 |
| Rodríguez, R | 1 |
| Willers, C | 1 |
| Dirschka, T | 1 |
| Samorano, LP | 1 |
| Torezan, LA | 1 |
| Sanches, JA | 1 |
| Stockfleth, E | 1 |
| Sibbring, GC | 1 |
| Alarcon, I | 1 |
| Floristan, U | 1 |
| Feltes, RA | 1 |
| Sendagorta, E | 1 |
| Feito-Rodriguez, M | 1 |
| Ramírez-Marín, P | 1 |
| Vidaurrázaga, C | 1 |
| Casado-Jiménez, M | 1 |
| Kaur, RR | 1 |
| Alikhan, A | 1 |
| Maibach, HI | 1 |
| Nikkhah, D | 1 |
| Abood, A | 1 |
| Watt, D | 1 |
| Al-Niaimi, F | 1 |
| Lyon, C | 1 |
| Lewis, KG | 1 |
| Lewis, MD | 1 |
| Robinson-Bostom, L | 1 |
| Pan, TD | 1 |
| Apikian, M | 1 |
| Goodman, G | 1 |
| Jorizzo, J | 1 |
| Weiss, J | 1 |
| Furst, K | 1 |
| VandePol, C | 1 |
| Levy, SF | 1 |
| Jury, CS | 1 |
| Ramraka-Jones, VS | 1 |
| Gudi, V | 1 |
| Herd, RM | 1 |
| Smith, SR | 1 |
| Morhenn, VB | 1 |
| Piacquadio, DJ | 1 |
| Gupta, AK | 2 |
| Davey, V | 1 |
| Mcphail, H | 1 |
| Epstein, E | 2 |
| Tanghetti, E | 1 |
| Werschler, P | 1 |
| Zide, MF | 1 |
| Chiaffitelli, C | 1 |
| Suarez Halty, L | 1 |
| Galentine, P | 1 |
| Sloas, H | 1 |
| Hargett, N | 1 |
| Cupples, HP | 1 |
| Monheit, GD | 1 |
| Reichert, S | 1 |
| Truchetet, F | 1 |
| Cuny, JF | 1 |
| Grandidier, M | 1 |
| Lawrence, N | 2 |
| Cox, SE | 2 |
| Cockerell, CJ | 2 |
| Freeman, RG | 1 |
| Cruz, PD | 1 |
| Hecker, D | 1 |
| Hacker, SM | 1 |
| Ramos-Caro, FA | 1 |
| Flowers, FP | 1 |
| Witheiler, DD | 1 |
| Cruz, C | 1 |
| Freemen, RG | 1 |
| Janmeja, M | 1 |
| Licata, A | 1 |
| Anderson, SH | 1 |
| Hudson-Peacock, M | 1 |
| Muller, AF | 1 |
| Chiarello, SE | 1 |
| Weiss, JS | 1 |
| Jorizzo, JL | 1 |
| De Ascensão, AC | 1 |
| Breza, T | 1 |
| Taylor, R | 1 |
| Eaglstein, WH | 1 |
| Pearlman, DL | 1 |
| Grattan, CE | 1 |
| Guerrier, CJ | 1 |
| Parker, CM | 1 |
| Hanke, CW | 1 |
| Sevadjian, CM | 1 |
| Nordlund, JJ | 1 |
| Klaus, SN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial[NCT00847912] | Phase 4 | 954 participants (Actual) | Interventional | 2009-06-26 | Completed | ||
| Aminolevulinic Acid-photodynamic Therapy for Facial Actinic Keratosis Treatment and Prevention: A Long-term (3 Years) Follow-up of Prospective, Randomized, Multicenter-clinical Trial[NCT03642535] | Phase 4 | 300 participants (Anticipated) | Interventional | 2018-08-30 | Recruiting | ||
| A Prospective Comparator Controlled Randomized Exploratory Study on the Efficacy of LAS 41005 Compared to Cryotherapy in Subjects With Hyperkeratotic Actinic Keratosis[NCT01358851] | Phase 2 | 67 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| Evaluation of the Tolerability and Safety of 0.015% Ingenol Mebutate Gel Compared to 5% 5-fluorouracil Cream for the Treatment of Facial Actinic Keratosis: a Prospective Randomized Trial[NCT02242747] | 100 participants (Actual) | Interventional | 2014-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00847912)
Timeframe: date of randomization to last visit before end of study follow up (6/30/2013), assessed up to four years
| Intervention | participants (Number) |
|---|---|
| Arm 1: 5-fluorouracil | 182 |
| Arm 2: Placebo, Vehicle Control | 177 |
Diagnosis of the first Primary Basil Cell Carcinoma (BCC) or primary Squamous Cell Carcinoma (SCC) on the face or ears that was removed surgically. (NCT00847912)
Timeframe: From randomization to last visit prior to end of study date (6/30/2013), assessed up to four years
| Intervention | years (Median) |
|---|---|
| Arm 1: 5-fluorouracil | 3.37 |
| Arm 2: Placebo, Vehicle Control | 3.52 |
4 reviews available for fluorouracil and Facial Dermatoses
| Article | Year |
|---|---|
New Topical Treatment Options for Actinic Keratosis: A Systematic Review.
Topics: Administration, Cutaneous; Aminoquinolines; Dermatologic Agents; Diterpenes; Drug Combinations; Faci | 2016 |
Comparison of topical 5-fluorouracil formulations in actinic keratosis treatment.
Topics: Administration, Cutaneous; Clinical Trials as Topic; Dermatologic Agents; Facial Dermatoses; Fluorou | 2010 |
Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies.
Topics: Adjuvants, Immunologic; Aminoquinolines; Clinical Trials, Phase III as Topic; Confidence Intervals; | 2005 |
5-fluorouracil 0.5% cream for multiple actinic or solar keratoses of the face and anterior scalp.
Topics: Facial Dermatoses; Fluorouracil; Humans; Keratosis; Scalp Dermatoses | 2001 |
10 trials available for fluorouracil and Facial Dermatoses
| Article | Year |
|---|---|
A prospective randomized exploratory study comparing the efficacy of once-daily topical 0.5% 5-fluorouracil in combination with 10.0% salicylic acid (5-FU/SA) vs. cryosurgery for the treatment of hyperkeratotic actinic keratosis.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Cryosurgery; Drug Combinations; Facial Dermatose | 2015 |
Evaluation of the tolerability and safety of a 0.015% ingenol mebutate gel compared to 5% 5-fluorouracil cream for the treatment of facial actinic keratosis: a prospective randomized trial.
Topics: Administration, Topical; Diterpenes; Drug Tolerance; Facial Dermatoses; Fluorouracil; Follow-Up Stud | 2015 |
Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined | 2004 |
A randomized trial of topical 5% 5-fluorouracil (Efudix cream) in the treatment of actinic keratoses comparing daily with weekly treatment.
Topics: Aged; Aged, 80 and over; Antimetabolites; Drug Administration Schedule; Facial Dermatoses; Female; F | 2005 |
Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Diclofenac; Facial Dermato | 2006 |
Twice daily vs. four times daily 5-fluorouracil therapy for actinic keratoses: a split face study.
Topics: Aged; Antimetabolites; Drug Administration Schedule; Facial Dermatoses; Female; Fluorouracil; Humans | 2006 |
Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp.
Topics: Administration, Topical; Adult; Aminoquinolines; Disease Management; Erythema; Facial Dermatoses; Fl | 2007 |
A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses.
Topics: Drug Combinations; Ethanol; Facial Dermatoses; Fluorouracil; Follow-Up Studies; Humans; Keratosis; L | 1995 |
Patient survey of trichloroacetic acid treatment of facial actinic keratoses.
Topics: Caustics; Facial Dermatoses; Fluorouracil; Humans; Keratosis; Patient Satisfaction; Sunlight; Trichl | 1999 |
Noninflammatory destruction of actinic keratoses by fluorouracil.
Topics: Aged; Drug Combinations; Facial Dermatoses; Female; Fluorouracil; Humans; Keratosis; Male; Middle Ag | 1976 |
25 other studies available for fluorouracil and Facial Dermatoses
| Article | Year |
|---|---|
A Case of Melkersson-Rosenthal Syndrome Treated With 5-FU.
Topics: Antimetabolites; Dermatologic Agents; Facial Dermatoses; Fluorouracil; Humans; Male; Melkersson-Rose | 2021 |
5-Fluorouracil for Actinic Keratosis Treatment and Chemoprevention: A Randomized Controlled Trial.
Topics: Administration, Cutaneous; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Double | 2017 |
5-Fluorouracil for Actinic Keratosis Treatment and Chemoprevention: A Randomized Controlled Trial.
Topics: Administration, Cutaneous; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Double | 2017 |
5-Fluorouracil for Actinic Keratosis Treatment and Chemoprevention: A Randomized Controlled Trial.
Topics: Administration, Cutaneous; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Double | 2017 |
5-Fluorouracil for Actinic Keratosis Treatment and Chemoprevention: A Randomized Controlled Trial.
Topics: Administration, Cutaneous; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Double | 2017 |
Combination Therapies: Laser-Assisted Delivery of 5-Fluorouracil.
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Dermatologic Agents; Facial Dermatoses; Female; | 2019 |
Intralesional 5-fluorouracil to treat extensive molluscum contagiosum in an immunocompromised patient: A novel therapeutic modality.
Topics: Antimetabolites; Facial Dermatoses; Female; Fluorouracil; HIV Infections; Humans; Immunocompromised | 2018 |
Subacute cutaneous lupus erythematosus induced by capecitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Erupt | 2009 |
Cicatricial ectropion: a complication of topical 5-fluorouracil.
Topics: Administration, Topical; Aged, 80 and over; Cicatrix; Ectropion; Facial Dermatoses; Fluorouracil; Fo | 2012 |
Resolving actinic keratoses: an expected side-effect of capecitabine therapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidin | 2012 |
Inflammation of actinic keratoses during capecitabine therapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxyc | 2004 |
Intralesional 5-fluorouracil in the treatment of keloid scars.
Topics: Acne Keloid; Adult; Antimetabolites; Betamethasone; Facial Dermatoses; Female; Fluorouracil; Follow- | 2004 |
Actinic keratosis: from the skin to the lip.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biopsy; Chemexfoliation; Cryosurgery; Elec | 2008 |
[Experience on topical 5-fluoruracil- (5-FU) in cutaneous carcinomatosis. I. Test on the efficiency of topical 5-FU].
Topics: Carcinoma, Basal Cell; Cheilitis; Facial Dermatoses; Female; Fluorouracil; Hand Dermatoses; Humans; | 1966 |
Hidden fluorouracil applications as a cause of dermatitis and erosions.
Topics: Administration, Topical; Aged; Drug Eruptions; Facial Dermatoses; Female; Fluorouracil; Humans; Male | 1983 |
Bilateral cicatricial ectropion following topical administration of 5-fluorouracil.
Topics: Administration, Topical; Aged; Cicatrix; Drug Eruptions; Ectropion; Facial Dermatoses; Fluorouracil; | 1981 |
Facial blemishes and their treatment.
Topics: Carcinoma, Basal Cell; Chemexfoliation; Cryosurgery; Curettage; Electrosurgery; Facial Dermatoses; F | 1980 |
[Carcinoid tumor with revealed by skin manifestation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Combined Modality Therapy; Facial D | 1994 |
Temporary ectropion due to topical fluorouracil.
Topics: Administration, Cutaneous; Aged; Ectropion; Facial Dermatoses; Fluorouracil; Humans; Keratosis; Male | 1994 |
Long-term efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses.
Topics: Administration, Topical; Chemexfoliation; Drug Combinations; Ethanol; Facial Dermatoses; Fluorouraci | 1997 |
Malignant acanthosis nigricans: potential role of chemotherapy.
Topics: Acanthosis Nigricans; Aged; Anal Canal; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic | 1999 |
Cryopeeling (extensive cryosurgery) for treatment of actinic keratoses: an update and comparison.
Topics: Carcinoma, Squamous Cell; Chemexfoliation; Cryosurgery; Facial Dermatoses; Female; Fluorouracil; Fol | 2000 |
[Non hereditary porokeratosis of Mibelli].
Topics: Adolescent; Adult; Aged; Child; Facial Dermatoses; Female; Fluorouracil; Humans; Keratosis; Lip Dise | 1978 |
Weekly pulse dosing: effective and comfortable topical 5-fluorouracil treatment of multiple facial actinic keratoses.
Topics: Administration, Cutaneous; Drug Administration Schedule; Erythema; Facial Dermatoses; Fluorouracil; | 1991 |
Reaction to topical fluorouracil of secondary lymphedema.
Topics: Aged; Drug Eruptions; Facial Dermatoses; Female; Fluorouracil; Humans; Lymphedema; Ointments | 1985 |
Large keratoacanthomas in difficult locations treated with intralesional 5-fluorouracil.
Topics: Adult; Aged; Facial Dermatoses; Fluorouracil; Follow-Up Studies; Humans; Injections; Keratoacanthoma | 1986 |
Pustular contact hypersensitivity to fluorouracil with rosacealike sequelae.
Topics: Administration, Topical; Dermatitis, Contact; Drug Hypersensitivity; Facial Dermatoses; Female; Fluo | 1985 |
Successful topical treatment of an unusual ulcer with fluorouracil.
Topics: Diagnosis, Differential; Facial Dermatoses; Fluorouracil; Humans; Male; Skin; Skin Neoplasms; Skin U | 1972 |